Pegozafermin Sales Forecast, and Market Size Analysis – 2034
Description
Key Factors Driving Pegozafermin Growth
1. Differentiated FGF21 Analog Targeting Multiple Metabolic Pathways
Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) that regulates:
Lipid metabolism
Glucose homeostasis
Hepatic fat accumulation
Multi-pathway mechanism enables broad cardiometabolic and liver disease applicability
Differentiates it from single-target therapies (e.g., pure lipid or glucose agents)
2. Strong Efficacy in Severe Hypertriglyceridemia (sHTG)
Phase II (ENTRIGUE) data showed:
~57% median triglyceride reduction vs ~12% placebo (p<0.001)
Up to 79.7% of patients achieved TG <500 mg/dL vs 29.4% placebo
Among the most robust TG reductions reported in clinical trials
Strong positioning in high-risk patients (e.g., pancreatitis risk)
3. Clinically Meaningful Outcomes in NASH / MASH (Fibrosis + Resolution)
In Phase IIb (ENLIVEN trial):
Fibrosis improvement ≥1 stage in ~22–27% vs ~7% placebo
NASH resolution in ~23–37% vs ~2% placebo
Demonstrates disease-modifying potential, not just biomarker improvement
Critical for regulatory approval in MASH (NASH), a high-value market
4. Significant Reduction in Liver Fat and Atherogenic Lipids
~42% reduction in liver fat fraction vs ~8% placebo
Decreases in apoB and non-HDL cholesterol
Addresses both hepatic and cardiovascular risk factors
Enhances value proposition vs single-endpoint therapies
5. Broad Indication Expansion (sHTG + MASH + Cirrhosis)
Pegozafermin is being developed across:
Severe hypertriglyceridemia (sHTG)
Metabolic dysfunction–associated steatohepatitis (MASH/NASH)
Compensated cirrhosis (Phase 3 ongoing)
Combines large population (MASH) + high-value niche (sHTG)
Expands total addressable market significantly
Pegozafermin Recent Developments
In September 2025, Roche entered into a definitive merger agreement to acquire 89bio, a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage). The transaction is expected to close in the fourth quarter of 2025.
“Pegozafermin Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Pegozafermin for potential indication like Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer in the 7MM. A detailed picture of Pegozafermin’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Pegozafermin for potential indications. The Pegozafermin market report provides insights about Pegozafermin’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Pegozafermin performance, future market assessments inclusive of the Pegozafermin market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Pegozafermin sales forecasts, along with factors driving its market.
Pegozafermin Drug Summary
Pegozafermin is an investigational, long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of metabolic liver diseases, including metabolic dysfunction–associated steatohepatitis (MASH, formerly NASH) and severe hypertriglyceridemia. It acts by activating FGF21 pathways involved in regulating lipid metabolism, glucose homeostasis, and energy balance, leading to reductions in liver fat content, triglyceride levels, and markers of liver inflammation and fibrosis. Administered via subcutaneous injection, pegozafermin has demonstrated promising results in clinical trials, including significant improvements in hepatic steatosis and lipid parameters, along with a generally favorable safety and tolerability profile. The therapy is currently in late-stage clinical development, with ongoing studies evaluating its potential to address unmet needs in cardiometabolic and liver diseases. The report provides Pegozafermin’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Pegozafermin Market Report
The report provides insights into:
A comprehensive product overview including the Pegozafermin MoA, description, dosage and administration, research and development activities in potential indication like Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer.
Elaborated details on Pegozafermin regulatory milestones and other development activities have been provided in Pegozafermin market report.
The report also highlights Pegozafermin‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
The Pegozafermin market report also covers the patents information, generic entry and impact on cost cut.
The Pegozafermin market report contains current and forecasted Pegozafermin sales for potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Pegozafermin market report also features the SWOT analysis with analyst views for Pegozafermin in potential indications.
Methodology
The Pegozafermin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Pegozafermin Analytical Perspective by DelveInsight
In-depth Pegozafermin Market Assessment
This Pegozafermin sales market forecast report provides a detailed market assessment of Pegozafermin for potential indication like Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Pegozafermin sales data uptil 2034.
Pegozafermin Clinical Assessment
The Pegozafermin market report provides the clinical trials information of Pegozafermin for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Pegozafermin Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Pegozafermin Market Potential & Revenue Forecast
Projected market size for the Pegozafermin and its key indications
Estimated Pegozafermin sales potential (Pegozafermin peak sales forecasts)
Pegozafermin Pricing strategies and reimbursement landscape
Pegozafermin Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Pegozafermin Market positioning compared to existing treatments
Pegozafermin Strengths & weaknesses relative to competitors
Pegozafermin Regulatory & Commercial Milestones
Pegozafermin Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Pegozafermin Clinical Differentiation
Pegozafermin Efficacy & safety advantages over existing drugs
Pegozafermin Unique selling points
Pegozafermin Market Report Highlights
In the coming years, the Pegozafermin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Pegozafermin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pegozafermin’s dominance.
Other emerging products for Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer are expected to give tough market competition to Pegozafermin and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pegozafermin in potential indications.
Analyse Pegozafermin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Pegozafermin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Pegozafermin in potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Pegozafermin? How strong is Pegozafermin’s clinical and commercial performance?
What is Pegozafermin’s clinical trial status in each individual indications such as Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pegozafermin Manufacturers?
What are the key designations that have been granted to Pegozafermin for potential indications? How are they going to impact Pegozafermin’s penetration in various geographies?
What is the current and forecasted Pegozafermin market scenario for potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Pegozafermin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Pegozafermin for potential indications?
Which are the late-stage emerging therapies under development for the treatment of potential indications?
How cost-effective is Pegozafermin? What is the duration of therapy and what are the geographical variations in cost per patient?
1. Differentiated FGF21 Analog Targeting Multiple Metabolic Pathways
Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) that regulates:
Lipid metabolism
Glucose homeostasis
Hepatic fat accumulation
Multi-pathway mechanism enables broad cardiometabolic and liver disease applicability
Differentiates it from single-target therapies (e.g., pure lipid or glucose agents)
2. Strong Efficacy in Severe Hypertriglyceridemia (sHTG)
Phase II (ENTRIGUE) data showed:
~57% median triglyceride reduction vs ~12% placebo (p<0.001)
Up to 79.7% of patients achieved TG <500 mg/dL vs 29.4% placebo
Among the most robust TG reductions reported in clinical trials
Strong positioning in high-risk patients (e.g., pancreatitis risk)
3. Clinically Meaningful Outcomes in NASH / MASH (Fibrosis + Resolution)
In Phase IIb (ENLIVEN trial):
Fibrosis improvement ≥1 stage in ~22–27% vs ~7% placebo
NASH resolution in ~23–37% vs ~2% placebo
Demonstrates disease-modifying potential, not just biomarker improvement
Critical for regulatory approval in MASH (NASH), a high-value market
4. Significant Reduction in Liver Fat and Atherogenic Lipids
~42% reduction in liver fat fraction vs ~8% placebo
Decreases in apoB and non-HDL cholesterol
Addresses both hepatic and cardiovascular risk factors
Enhances value proposition vs single-endpoint therapies
5. Broad Indication Expansion (sHTG + MASH + Cirrhosis)
Pegozafermin is being developed across:
Severe hypertriglyceridemia (sHTG)
Metabolic dysfunction–associated steatohepatitis (MASH/NASH)
Compensated cirrhosis (Phase 3 ongoing)
Combines large population (MASH) + high-value niche (sHTG)
Expands total addressable market significantly
Pegozafermin Recent Developments
In September 2025, Roche entered into a definitive merger agreement to acquire 89bio, a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage). The transaction is expected to close in the fourth quarter of 2025.
“Pegozafermin Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Pegozafermin for potential indication like Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer in the 7MM. A detailed picture of Pegozafermin’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Pegozafermin for potential indications. The Pegozafermin market report provides insights about Pegozafermin’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Pegozafermin performance, future market assessments inclusive of the Pegozafermin market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Pegozafermin sales forecasts, along with factors driving its market.
Pegozafermin Drug Summary
Pegozafermin is an investigational, long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of metabolic liver diseases, including metabolic dysfunction–associated steatohepatitis (MASH, formerly NASH) and severe hypertriglyceridemia. It acts by activating FGF21 pathways involved in regulating lipid metabolism, glucose homeostasis, and energy balance, leading to reductions in liver fat content, triglyceride levels, and markers of liver inflammation and fibrosis. Administered via subcutaneous injection, pegozafermin has demonstrated promising results in clinical trials, including significant improvements in hepatic steatosis and lipid parameters, along with a generally favorable safety and tolerability profile. The therapy is currently in late-stage clinical development, with ongoing studies evaluating its potential to address unmet needs in cardiometabolic and liver diseases. The report provides Pegozafermin’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Pegozafermin Market Report
The report provides insights into:
A comprehensive product overview including the Pegozafermin MoA, description, dosage and administration, research and development activities in potential indication like Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer.
Elaborated details on Pegozafermin regulatory milestones and other development activities have been provided in Pegozafermin market report.
The report also highlights Pegozafermin‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
The Pegozafermin market report also covers the patents information, generic entry and impact on cost cut.
The Pegozafermin market report contains current and forecasted Pegozafermin sales for potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Pegozafermin market report also features the SWOT analysis with analyst views for Pegozafermin in potential indications.
Methodology
The Pegozafermin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Pegozafermin Analytical Perspective by DelveInsight
In-depth Pegozafermin Market Assessment
This Pegozafermin sales market forecast report provides a detailed market assessment of Pegozafermin for potential indication like Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Pegozafermin sales data uptil 2034.
Pegozafermin Clinical Assessment
The Pegozafermin market report provides the clinical trials information of Pegozafermin for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Pegozafermin Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Pegozafermin Market Potential & Revenue Forecast
Projected market size for the Pegozafermin and its key indications
Estimated Pegozafermin sales potential (Pegozafermin peak sales forecasts)
Pegozafermin Pricing strategies and reimbursement landscape
Pegozafermin Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Pegozafermin Market positioning compared to existing treatments
Pegozafermin Strengths & weaknesses relative to competitors
Pegozafermin Regulatory & Commercial Milestones
Pegozafermin Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Pegozafermin Clinical Differentiation
Pegozafermin Efficacy & safety advantages over existing drugs
Pegozafermin Unique selling points
Pegozafermin Market Report Highlights
In the coming years, the Pegozafermin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Pegozafermin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pegozafermin’s dominance.
Other emerging products for Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer are expected to give tough market competition to Pegozafermin and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pegozafermin in potential indications.
Analyse Pegozafermin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Pegozafermin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Pegozafermin in potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Pegozafermin? How strong is Pegozafermin’s clinical and commercial performance?
What is Pegozafermin’s clinical trial status in each individual indications such as Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pegozafermin Manufacturers?
What are the key designations that have been granted to Pegozafermin for potential indications? How are they going to impact Pegozafermin’s penetration in various geographies?
What is the current and forecasted Pegozafermin market scenario for potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Pegozafermin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Pegozafermin for potential indications?
Which are the late-stage emerging therapies under development for the treatment of potential indications?
How cost-effective is Pegozafermin? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
30 Pages
- 1. Report Introduction
- 2. Pegozafermin Overview in potential indication like Hypertriglyceridaemia, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease and Liver cancer
- 2.1. Product Detail
- 2.2. Pegozafermin Clinical Development
- 2.2.1. Pegozafermin Clinical studies
- 2.2.2. Pegozafermin Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
- 3. Pegozafermin Competitive Landscape (Marketed Therapies)
- 4. Competitive Landscape (Late-stage Emerging Pegozafermin Therapies)
- 5. Pegozafermin Market Assessment
- 5.1. Pegozafermin Market Outlook in potential indications
- 5.2. 7MM Analysis
- 5.2.1. Pegozafermin Market Size in the 7MM for potential indications
- 5.3. Country-wise Market Analysis
- 5.3.1. Pegozafermin Market Size in the United States for potential indications
- 5.3.2. Pegozafermin Market Size in Germany for potential indications
- 5.3.3. Pegozafermin Market Size in France for potential indications
- 5.3.4. Pegozafermin Market Size in Italy for potential indications
- 5.3.5. Pegozafermin Market Size in Spain for potential indications
- 5.3.6. Pegozafermin Market Size in the United Kingdom for potential indications
- 5.3.7. Pegozafermin Market Size in Japan for potential indications
- 6. Pegozafermin SWOT Analysis
- 7. Analysts’ Views
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
- 12. Report Purchase Options
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
